Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
1.9
%
10,44%
Latest
20.1
High
20.9
Low
17.85
Volume
690 621
Turnover (SEK)
13 496 050
Value (MSEK)
645,9

Board

CEO

  • Bo Rode Hansen

Chairman Of The Board

  • Peter Høngaard

Board

  • Annie Rasmussen
  • Bo Hansen
  • Carl Borrebäck
  • Christian Vinding Thomsen
  • Jørgen Bardenfleth
  • Thomas Feldthus

Videos

Largest Owners

Name Capital % Votes % Date
Avanza Pension 5,71 5,71 2020-03-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2021-02-18 Bokslutskommuniké 2020

  • 2021-05-20 Delårsrapport 2021-Q1

  • 2021-05-26 Årsstämma 2020

  • 2021-08-19 Delårsrapport 2021-Q2

  • 2021-11-18 Delårsrapport 2021-Q3

  • 2022-02-16 Bokslutskommuniké 2021